Gufic Biosciences Q2 FY27: revenue up 21.6% to ₹288 Cr, net profit up 39.5% to ₹24 Cr
Results · 16 Nov 2026 · Gufic Biosciences (GUFICBIO)
| Q2 FY27 | ₹ Cr | YoY |
|---|---|---|
| Revenue | 288 | +21.6% |
| Operating profit | 49 | +28.2% |
| Net profit | 24 | +39.5% |
In Q2 FY27, revenue from operations rose to INR 288.4 crore from INR 230.4 crore in Q2 FY26, EBITDA grew to INR 49.7 crore at a 17.23% margin, and PAT increased to INR 23.5 crore at an 8.15% margin.
Indore achieved EBITDA breakeven in Q2 FY27 and is expected to cover interest and depreciation by Q4, while completing its USFDA pre-approval inspection with three non-critical observations.
EBITDA margin dipped around 0.9% from 18.1% to 17.23% due to higher imported API costs from rupee devaluation and increased transport expenses, which management expects to normalize by Q4.
Company page · Results tracker
Anand Ganapathy K | SEBI Registered Research Analyst | INH000016630.